论文部分内容阅读
肺炎球菌结合菌苗(PCV)可以安全有效地减少肺炎链球菌引起的肺炎发病和死亡。WHO推荐和GAVI联盟(一个资助最低收入国家研制使用疫苗的公立和私人伙伴财团)的资助,使越来越多的国家将PCV纳入国家免疫规划中,尤其在低收入国家获得的新疫苗配方还可以预防通常发生在低、中等收入国家的更多血清型引起的肺炎。本报告采用WHO数据,描述了2000-2012年全球PCV使用的进展情况,按照各国疾病数据特征和世界银行各
Pneumococcal conjugate vaccine (PCV) can be safely and effectively reduce the incidence of pneumonia and pneumonia caused by pneumonia and death. The WHO recommendation and funding from the GAVI Alliance, a consortium of public and private financial partners that have developed vaccines in the lowest-income countries, have led more and more countries to include PCV in their national immunization programs, especially in low-income countries It is possible to prevent more serotypes of pneumonia that usually occur in low- and middle-income countries. This report uses WHO data to describe the progress of global PCV use from 2000 to 2012. According to the characteristics of national disease data and the World Bank